- Home
- NFBK vs PRTA Comparison
NFBK vs PRTA Comparison
Compare NFBK & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NFBK | PRTA |
|---|---|---|
| Founded | 1887 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 468.2M | 482.3M |
| IPO Year | 2010 | 2013 |
Fundamental Metrics
Financial Performance| Metric | NFBK | PRTA |
|---|---|---|
| Price | $13.33 | $9.48 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $13.50 | ★ $19.00 |
| AVG Volume (30 Days) | 335.2K | ★ 377.8K |
| Earning Date | 05-05-2026 | 05-20-2026 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $6,870,000.00 | $814,000.00 |
| Revenue This Year | $4.95 | $1,395.77 |
| Revenue Next Year | $6.32 | N/A |
| P/E Ratio | $674.00 | ★ N/A |
| Revenue Growth | ★ 6.84 | N/A |
| 52 Week Low | $9.40 | $4.32 |
| 52 Week High | $14.05 | $15.63 |
Technical Indicators
Market Signals| Indicator | NFBK | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 54.35 | 55.95 |
| Support Level | $13.23 | $8.23 |
| Resistance Level | $13.70 | $9.59 |
| Average True Range (ATR) | 0.24 | 0.55 |
| MACD | -0.08 | 0.10 |
| Stochastic Oscillator | 26.42 | 69.34 |
Price Performance
Historical ComparisonAbout NFBK Northfield Bancorp Inc. (Delaware)
Northfield Bancorp Inc is the holding company for Northfield Bank. Its subsidiary provides banking services to individuals and corporate customers in Richmond and Kings Counties in New York, and Hunterdon, Mercer, Union and Middlesex counties in New Jersey. The bank attracts deposits and offers credit and other banking services.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.